In about 25% of Erbb2 over expressing tumors (5/21), trastuzumab in combination with cetuximab resulted in a moderate antitumor effect in terms of reduction in tumor morphology and tumor cell proliferation with concomitant activation of cleaved caspase-3 (Fig. 4D). Here, CASP3 is linked to neoplasm.